Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Alkermes Inc (ALKS) since 2010 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Alkermes Inc. Table 2 shows the detailed insider transactions. This company's CIK number is 874663.
Total stock buying since 2010: $56,769.
Total stock sales since 2010: $7,049,370.
Total stock option exercises since 2010: $2,531,723.
▪ Statistics of price movements of ALKS
▪ Recent SEC 13D filings for all companies
▪ Recent portfolio reports of all companies
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2011 | 0 | $0 | 317,695 | $5,844,776 | 314,200 | $2,120,420 |
| 2010 | 5,000 | $56,769 | 87,494 | $1,204,594 | 79,620 | $411,303 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2011-07 | 0 | $0 | 143,250 | $2,710,979 | 130,225 | $1,008,272 |
| 2011-06 | 0 | $0 | 33,073 | $592,687 | 19,025 | $129,149 |
| 2011-05 | 0 | $0 | 141,372 | $2,541,110 | 164,950 | $982,999 |
| 2010-11 | 0 | $0 | 3,753 | $41,049 | 23,750 | $0 |
| 2010-10 | 0 | $0 | 5,000 | $75,000 | 0 | $0 |
| 2010-09 | 0 | $0 | 45,000 | $662,340 | 30,000 | $299,100 |
| 2010-08 | 0 | $0 | 5,000 | $65,550 | 0 | $0 |
| 2010-07 | 0 | $0 | 5,000 | $62,250 | 0 | $0 |
| 2010-06 | 0 | $0 | 23,741 | $298,405 | 15,245 | $112,203 |
| 2010-05 | 5,000 | $56,769 | 0 | $0 | 10,625 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2011-07-18 | Pugh Gordon G (SVP & COO) | Sale | 12,000 | 19.01 | 228,072 |
| 2011-07-18 | Pugh Gordon G (SVP & COO) | Option Ex | 12,000 | 7.36 | 88,320 |
| 2011-07-08 | Frates James M (SVP, CFO & Treasurer) | Sale | 200 | 20.00 | 4,000 |
| 2011-07-08 | Frates James M (SVP, CFO & Treasurer) | Option Ex | 200 | 4.77 | 953 |
| 2011-07-06 | Pugh Gordon G (SVP & COO) | Sale | 15,000 | 18.69 | 280,320 |
| 2011-07-06 | Pugh Gordon G (SVP & COO) | Option Ex | 15,000 | 8.55 | 128,250 |
| 2011-07-01 | Breyer Robert A (Director) | Sale | 6,050 | 18.55 | 112,227 |
| 2011-07-01 | Breyer Robert A (Director) | Option Ex | 3,025 | 7.19 | 21,749 |
| 2011-07-01 | Bloom Floyd E (Director) | Sale | 10,000 | 18.63 | 186,260 |
| 2011-07-01 | Biberstein Kathryn L (SVP, General Counsel) | Sale | 100,000 | 19.00 | 1,900,100 |
| 2011-07-01 | Biberstein Kathryn L (SVP, General Counsel) | Option Ex | 100,000 | 7.69 | 769,000 |
| 2011-06-30 | Bloom Floyd E (Director) | Sale | 10,000 | 18.14 | 181,360 |
| 2011-06-29 | Pugh Gordon G (SVP & COO) | Sale | 12,000 | 17.80 | 213,600 |
| 2011-06-29 | Pugh Gordon G (SVP & COO) | Option Ex | 12,000 | 7.36 | 88,320 |
| 2011-06-24 | Pugh Gordon G (SVP & COO) | Sale | 4,000 | 17.46 | 69,832 |
| 2011-06-24 | Pugh Gordon G (SVP & COO) | Option Ex | 4,000 | 4.77 | 19,080 |
| 2011-06-02 | Ehrich Elliot (SVP, R&D & Chief Medical Ofcr) | Sale | 1,023 | 17.80 | 18,209 |
| 2011-06-01 | Breyer Robert A (Director) | Sale | 6,050 | 18.13 | 109,686 |
| 2011-06-01 | Breyer Robert A (Director) | Option Ex | 3,025 | 7.19 | 21,749 |
| 2011-05-31 | Ehrich Elliot (SVP, R&D & Chief Medical Ofcr) | Sale | 1,023 | 18.16 | 18,577 |
| 2011-05-27 | Ehrich Elliot (SVP, R&D & Chief Medical Ofcr) | Sale | 1,450 | 18.02 | 26,129 |
| 2011-05-26 | Ehrich Elliot (SVP, R&D & Chief Medical Ofcr) | Option Ex | 2,125 | .00 | 0 |
| 2011-05-26 | Pugh Gordon G (SVP & COO) | Option Ex | 2,125 | .00 | 0 |
| 2011-05-26 | Landine Michael J (SVP, Corporate Development) | Option Ex | 2,125 | .00 | 0 |
| 2011-05-26 | Frates James M (SVP, CFO & Treasurer) | Option Ex | 2,125 | .00 | 0 |
| 2011-05-26 | Biberstein Kathryn L (SVP, General Counsel) | Option Ex | 2,125 | .00 | 0 |
| 2011-05-18 | Ehrich Elliot (SVP, R&D & Chief Medical Ofcr) | Sale | 2,849 | 18.05 | 51,424 |
| 2011-05-17 | Ehrich Elliot (SVP, R&D & Chief Medical Ofcr) | Option Ex | 4,175 | .00 | 0 |
| 2011-05-17 | Pugh Gordon G (SVP & COO) | Option Ex | 3,275 | .00 | 0 |
| 2011-05-17 | Landine Michael J (SVP, Corporate Development) | Option Ex | 3,250 | .00 | 0 |
| 2011-05-17 | Frates James M (SVP, CFO & Treasurer) | Option Ex | 4,350 | .00 | 0 |
| 2011-05-17 | Biberstein Kathryn L (SVP, General Counsel) | Option Ex | 3,125 | .00 | 0 |
| 2011-05-17 | Pops Richard F (President and CEO) | Option Ex | 8,125 | .00 | 0 |
| 2011-05-16 | Biberstein Kathryn L (SVP, General Counsel) | Sale | 116,200 | 18.01 | 2,092,645 |
| 2011-05-16 | Biberstein Kathryn L (SVP, General Counsel) | Option Ex | 116,200 | 7.69 | 893,578 |
| 2011-05-13 | Breyer Robert A (Director) | Sale | 6,050 | 18.00 | 108,900 |
| 2011-05-13 | Breyer Robert A (Director) | Option Ex | 3,025 | 7.19 | 21,749 |
| 2011-05-13 | Biberstein Kathryn L (SVP, General Counsel) | Sale | 8,800 | 18.00 | 158,435 |
| 2011-05-13 | Biberstein Kathryn L (SVP, General Counsel) | Option Ex | 8,800 | 7.69 | 67,672 |
| 2011-05-12 | Ehrich Elliot (SVP, R&D & Chief Medical Ofcr) | Sale | 5,000 | 17.00 | 85,000 |
| 2010-11-19 | Ehrich Elliot (SVP, R&D & Chief Medical Ofcr) | Sale | 3,412 | 10.83 | 36,951 |
| 2010-11-18 | Ehrich Elliot (SVP, R&D & Chief Medical Ofcr) | Option Ex | 5,000 | .00 | 0 |
| 2010-11-18 | Pugh Gordon G (SVP & COO) | Option Ex | 3,750 | .00 | 0 |
| 2010-11-18 | Landine Michael J (SVP, Corporate Development) | Option Ex | 5,000 | .00 | 0 |
| 2010-11-18 | Frates James M (SVP, CFO & Treasurer) | Option Ex | 6,250 | .00 | 0 |
| 2010-11-18 | Biberstein Kathryn L (SVP, General Counsel) | Option Ex | 3,750 | .00 | 0 |
| 2010-11-08 | Ehrich Elliot (SVP, R&D & Chief Medical Ofcr) | Sale | 341 | 12.02 | 4,098 |
| 2010-10-01 | Bloom Floyd E (Director) | Sale | 5,000 | 15.00 | 75,000 |
| 2010-09-17 | Ehrich Elliot (SVP, R&D & Chief Medical Ofcr) | Sale | 35,000 | 15.00 | 525,000 |
| 2010-09-17 | Ehrich Elliot (SVP, R&D & Chief Medical Ofcr) | Option Ex | 30,000 | 9.97 | 299,100 |
| 2010-09-13 | Ehrich Elliot (SVP, R&D & Chief Medical Ofcr) | Sale | 5,000 | 14.07 | 70,350 |
| 2010-09-01 | Bloom Floyd E (Director) | Sale | 5,000 | 13.40 | 66,990 |
| 2010-08-02 | Bloom Floyd E (Director) | Sale | 5,000 | 13.11 | 65,550 |
| 2010-07-01 | Bloom Floyd E (Director) | Sale | 5,000 | 12.45 | 62,250 |
| 2010-06-25 | Ehrich Elliot (SVP, R&D & Chief Medical Ofcr) | Sale | 15,245 | 13.00 | 198,185 |
| 2010-06-25 | Ehrich Elliot (SVP, R&D & Chief Medical Ofcr) | Option Ex | 15,245 | 7.36 | 112,203 |
| 2010-06-23 | Ehrich Elliot (SVP, R&D & Chief Medical Ofcr) | Sale | 3,496 | 12.32 | 43,070 |
| 2010-06-01 | Bloom Floyd E (Director) | Sale | 5,000 | 11.43 | 57,150 |
| 2010-05-26 | Ehrich Elliot (SVP, R&D & Chief Medical Ofcr) | Option Ex | 2,125 | .00 | 0 |
| 2010-05-26 | Pugh Gordon G (SVP & COO) | Option Ex | 2,125 | .00 | 0 |
| 2010-05-26 | Landine Michael J (SVP, Corporate Development) | Option Ex | 2,125 | .00 | 0 |
| 2010-05-26 | Frates James M (SVP, CFO & Treasurer) | Option Ex | 2,125 | .00 | 0 |
| 2010-05-26 | Biberstein Kathryn L (SVP, General Counsel) | Option Ex | 2,125 | .00 | 0 |
| 2010-05-19 | Anstice David W (Director) | Buy | 5,000 | 11.35 | 56,769 |
Insider trading activities including stock purchases, stock sales, and option exercises of ALKS listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Alkermes Inc (symbol ALKS, CIK number 874663) see the Securities and Exchange Commission (SEC) website.